Generative AI is transforming biopharma R&D, accelerating drug discovery, molecular modeling, and early-stage trial design. Startups like Insilico Medicine and Nabla Bio are using AI to identify novel targets, optimize compounds, and support predictive modeling for therapies faster than traditional approaches. As investors and pharma partners flock to this space, GenAI-driven platforms are reshaping timelines, lowering costs, and driving the next wave of breakthrough therapies in 2026.